AstraZeneca’s Imfinzi and Imjudo combinations have been recommended for marketing authorization in the European Union for advanced liver and lung cancers, the company announced. The concurrent positive opinions recommend authorizing Imfinzi in combination with Imjudo for 1st-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma, or HCC; and Imfinzi in combination with Imjudo and platinum-based chemotherapy for the treatment of adult patients with Stage IV non-small cell lung cancer, or NSCLC, AstraZeneca stated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for approval in the EU
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Deutsche Bank
- Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo
- AstraZeneca’s anifrolumab receives FDA orphan designation
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’